Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia

Published:2016-02-05 Issue:5 Volume:59 Page:1984-2004
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Liang Xiaofei¹²,Liu Xiaochuan¹³,Wang Beilei¹²,Zou Fengming¹²,Wang Aoli¹⁴,Qi Shuang¹²,Chen Cheng¹²,Zhao Zheng¹²,Wang Wenchao¹²,Qi Ziping¹²,Lv Fengchao¹⁴,Hu Zhenquan¹²,Wang Li¹²,Zhang Shanchun²⁵,Liu Qingsong¹²⁴⁶,Liu Jing¹²

Affiliation:

1. High Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China

2. CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China

3. Department of Chemistry, University of Science and Technology of China, Hefei, Anhui 230036, P. R. China

4. University of Science and Technology of China, P. R. China, Anhui Hefei 230036, P. R. China

5. Hefei Cosource Medicine Technology Co. LTD., 358 Ganquan Road, Hefei, Anhui 230031, P. R. China

6. Hefei Science Center, Chinese Academy of Sciences, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Anhui Province

Chinese Academy of Sciences

Hefei Science Center, Chinese Academy of Sciences

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01618

Reference22 articles.

1. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

2. Role of ABL family kinases in cancer: from leukaemia to solid tumours

3. The molecular biology of chronic myeloid leukemia

4. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia;Mini-Reviews in Medicinal Chemistry;2023-10-06

2. Identification of PARN nuclease activity inhibitors by computational-based docking and high-throughput screening;Scientific Reports;2023-03-31

3. Discovery of CZS-241: A Potent, Selective, and Orally Available Polo-Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia;Journal of Medicinal Chemistry;2023-02-03

4. A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia;Journal of Medicinal Chemistry;2022-09-12

5. PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML);Pharmaceutics;2022-08-10